Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan

Yoshiya Tanaka, Tsuneyo Mimori, Hisashi Yamanaka, Ryo Nakajima, Kazuo Morita, Junko Kimura, Tsutomu Takeuchi

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint Dive into the research topics of 'Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan'. Together they form a unique fingerprint.

Medicine & Life Sciences